Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 109

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 109
---
 vector and nucleic acid (mRNA and DNA) vaccines
are more novel platforms. The only viral vector vaccine licensed for human use is the Ebola vaccine by Merck.

The success of the vaccines from Pfizer-BioNTech
(BNT162b2, also known as Comirnaty®) and Moderna (mRNA-1273, also known as Spikevax®) in combatting Coronavirus has demonstrated
the value and rapid translational potential of lipid nanoparticles.

The Coronavirus pandemic introduced many millions
of people to mRNA vaccines, saving many lives. These vaccines consist of two main components:

| - | An mRNA molecule, a fragile single                                                               
 strand polymer of nucleic acid that instructs the host cells to produce predetermined protein(s) |

| - | A lipid nanoparticles (LNPs) coating                                   
 that enables an efficient delivery of nucleic acids into living cells. |

<div align='center'>70</div>

Upon injection these vaccines into the muscle,
the mRNA in the vaccine is taken up by muscle cells and muscle immune cells that start producing the desired protein and displaying it
to specialized immune cells. Despite of wide vaccination with the newly introduced mRNA vaccines, since 2020, the rapid evolution and
spread of new Covid variants have caused severe illnesses and national lockdowns, proving to the world how critical it is to prepare
for future potential pandemics.

Mutations of other dangerous viruses that are
easily transferred from animals to humans, such as bird flu, can erupt at any moment, bringing the global healthcare system to the brink
of collapse, as well as triggering a social and economic crisis similar to what occurred during Covid. New mutations of known deadly
viral diseases, such as Ebola, can pose a rapid and aggressive threat to the entire world.

Novel Approach: LPLT by LipoVation

Our team has been focusing on the development
of Liposomal Protein-Loaded Technology (LPLT), a novel immunization platform that we are evaluating for potential use in developing vaccines
against a variety of viral diseases, including Coronavirus, West Nile Virus, Zika, HIV and others. The platform incorporates a proprietary
lipid and a CCS-based delivery system designed to protect virus-specific antigens and support their delivery. This approach may enable
coverage of a broader range of antigens, beyond the spike protein, which could potentially improve the breadth of immune responses. However,
this program remains at a preclinical stage, and there can be no assurance that these features will translate into safety or